1833.HK Ping An (HKSE) +3.04% after hrs 10 Feb 2026: earnings test margins

We see 1833.HK stock trade higher in after-hours action on 10 Feb 2026, rising 3.04% to HKD 14.25 as the market positions ahead of an earnings release due 11 Feb 2026. Volume today reached 11,310,800 shares versus an average of 16,510,963, showing selective investor interest. The coming report will be read for revenue growth, margins and guidance, and we focus this earnings spotlight on valuation, cash flow metrics and what a beat or miss could mean for the Hong Kong-listed Ping An Healthcare and Technology Company Limited (HKSE)

Earnings catalyst: 1833.HK stock heads into results

Ping An Healthcare and Technology (1833.HK stock) reports earnings on 11 Feb 2026 and traders pushed the price to HKD 14.25 in after-hours trade on 10 Feb 2026. The company lists an EPS of 0.10 and a trailing PE of 142.50, so investors will watch margin trends and guidance closely. A stronger-than-expected top line or margin improvement could re-rate the stock given its growth history

Valuation snapshot and key financial ratios for 1833.HK stock

The headline valuation for 1833.HK stock shows a market cap near HKD 30.30 billion and a price-to-book of 2.58 with book value per share 4.88 HKD. Profitability is slim relative to price: net income per share is 0.08 HKD, price-to-sales is 5.14, and free cash flow per share is 0.14 HKD, highlighting a premium multiple. The balance sheet is strong by liquidity metrics with a current ratio of 3.15, net debt effectively negative and interest coverage at 11.53

Meyka AI rates 1833.HK with a score out of 100 and what it means

Meyka AI rates 1833.HK with a score out of 100: the model scores 70.26 with a grade B+ and a suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade does not guarantee outcomes and is informational only; we note the model rewards cash reserves and growth but flags high PE as a valuation risk

Meyka AI’s forecast model projects prices and implied upside for 1833.HK stock

Meyka AI’s forecast model projects a yearly target of HKD 20.87, a monthly near HKD 17.11 and a three-year view of HKD 33.37. Against the current HKD 14.25, the one-year projection implies an upside of 46.46% to HKD 20.87. Forecasts are model-based projections and not guarantees; treat them as scenario inputs for portfolio planning

Technicals and trading setup for 1833.HK stock

Technically, 1833.HK stock shows momentum but is near overbought readings: RSI 71.57 and MACD histogram positive at 0.33, with average price over 50 days at HKD 15.04 and 200-day at HKD 13.49. Short-term support sits near the day low HKD 13.85 and resistance near the intraday high HKD 14.35 and the Bollinger upper band at HKD 16.90. Traders should watch volume — today 11,310,800 vs average 16,510,963 — to confirm moves after the earnings print

Risks and opportunities in the Ping An Healthcare (1833.HK stock) story

Opportunity: digital healthcare adoption in China and Ping An’s diversified services can drive higher monetization and faster revenue per user, supporting our growth cases. Risk: the stock’s stretched PE and sensitivity to margin beats mean any signs of slower monetization, regulatory changes or weaker guidance may trigger sharp downside. We view sector comparisons cautiously: healthcare peer P/E averages are lower, so execution matters for re-rating

Final Thoughts

Key takeaways on 1833.HK stock: Ping An Healthcare and Technology closed after hours at HKD 14.25 on 10 Feb 2026, up 3.04%, as investors position for the 11 Feb 2026 earnings release. Valuation remains rich with a trailing PE near 142.50 and limited earnings per share (0.10 HKD), but the balance sheet, cash flow generation and high current ratio provide downside buffers. Meyka AI’s model projects a one-year target of HKD 20.87, implying 46.46% upside versus today’s price; this is a model-based projection and not a guarantee. For earnings-driven trading, we recommend watching revenue growth, margin trajectory and management guidance closely. Longer-term investors should weigh execution risk against sizable upside scenarios and consider position sizing to manage volatility in the Hong Kong healthcare technology sector. For live data and updates see our Meyka AI-powered market analysis and comparative reads on Investing.com compare pages and peer comparison. Forecasts are model outputs and not guarantees; perform your own due diligence before acting.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.